fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Nizatidine

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription

Axid · DIN 00778338 · 150 mg · capsule

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Axid · DIN 00778338 Manufacturer: Pendopharm, Division of Pharmascience Inc.; listing date 1996-10-01 Health Canada: Marketed since 2013-09-26 · brand AXID · ATC A02BA04 NIZATIDINE · form Capsule · route Oral · ingredients NIZATIDINE 150 MG · company Pendopharm division of pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Axid: Formulary list price $0.90 per unit (the source does not state the unit; exact figure $0.9047). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00778338)

Source record
DIN 00778338: Axid Raw flags: chronicUseMed=Y, sec3=Y Item: 564000027; group id 686; item number 1706; lccId None; manufacturer id PEN Source form: Cap; strength: 150mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.9047; ministry $0.9047 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00778338 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8915
Shortage status: resolved shortage (ended November 22, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00778338
Shortage record checked October 6, 2026

Axid · DIN 00778346 · 300 mg · capsule

General benefitDormant since August 3, 2017 · checked October 5, 2026 · What does dormant mean?
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Axid · DIN 00778346 Manufacturer: Pharmel Inc.; listing date 1996-10-01 Health Canada: Dormant since 2017-08-03 · brand AXID · ATC A02BA04 NIZATIDINE · form Capsule · route Oral · ingredients NIZATIDINE 300 MG · company Pendopharm division of pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Axid: Formulary list price $1.52 per unit (the source does not state the unit; exact figure $1.5206). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00778346)

Source record
DIN 00778346: Axid Raw flags: chronicUseMed=Y, sec3=Y Item: 564000028; group id 686; item number 1707; lccId None; manufacturer id PHE Source form: Cap; strength: 300mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.5206; ministry $1.5206 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00778346 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8916
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00778346
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since August 3, 2017 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (A02B, A02BA): coverage varies; not interchangeable

  • Cimetidine: general benefit, not a benefit
  • Famotidine (Pepcid): general benefit, not a benefit
  • Ranitidine (Zantac): general benefit, not a benefit
  • Misoprostol (Cytotec): general benefit, not a benefit
  • Pantoprazole (Tecta): general benefit
  • Rabeprazole (Pariet): general benefit

7 more in the class list below

Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered

Matched class: 56:40 Miscellaneous G.I. Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, OLSALAZINE SODIUM, PANTOPRAZOLE MAGNESIUM, RABEPRAZOLE SODIUM, SUCRALFATE Some products covered without a code (check the product listing): 5-AMINOSALICYLIC ACID, CIMETIDINE, DOMPERIDONE MALEATE, FAMOTIDINE, LACTULOSE, METOCLOPRAMIDE HCL, MISOPROSTOL, RANITIDINE HCL 56:40 Miscellaneous G.I. Drugs

CIMETIDINE

· 10 products · General benefit (5), Listed, not a benefit (5) · strengths: 200mg, 300mg, 400mg, 600mg, 800mg · Tab

FAMOTIDINE

· 16 products · Listed, not a benefit (2), General benefit (14) · strengths: 20mg, 40mg · Tab

RANITIDINE HCL

· 23 products · Listed, not a benefit (3), General benefit (20) · strengths: 15mg/mL, 150mg, 300mg · Oral Sol, Tab

MISOPROSTOL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mcg, 200mcg · Tab

PANTOPRAZOLE MAGNESIUM

· 6 products · General benefit · strengths: 40mg · Ent Coated Tab

RABEPRAZOLE SODIUM

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

SUCRALFATE

· 4 products · General benefit · strengths: 1g/5mL, 1g · Oral Susp, Tab

LANSOPRAZOLE

· 16 products · Limited Use, codes 293, 295, 297, 401, 402 · strengths: 15mg, 30mg · DR Cap

LANSOPRAZOLE & CLARITHROMYCIN & AMOXICILLIN

· 2 products · Listed, not a benefit (1), Limited Use, codes 306, 307 (1) · strengths: 30mg & 500mg & 500mg · Tab/Cap Pk

OMEPRAZOLE

· 19 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (2), Limited Use, codes 293, 297, 401, 402 (13) · strengths: 10mg, 20mg · DR Cap

PANTOPRAZOLE SODIUM

· 30 products · Off-Formulary Interchangeable, not an ODB benefit (10), Limited Use, codes 293, 295, 297, 401, 402 (20) · strengths: 20mg, 40mg · Ent Tab

DEXLANSOPRAZOLE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 30mg, 60mg · DR Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 56:40 and 10 more
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:22 Antiemetics and Antinauseants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS AXID (nizatidine capsules) is indicated for:  the treatment of conditions where a controlled reduction of gastric acid secretion is required such as for ulcer healing and/or pain relief: acute duodenal ulcer, acute benign gastric ulcer, gastroesophageal reflux disease and prophylactic use in duodenal ulcer. 1.1 Pediatrics Pediatrics (under 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use . 1.2 Geriatrics Geriatrics (over 65 years of age): Evidence from clinical studies and experience do not suggest that use in the geriatric population is associated with differences in safety or effectiveness . Age alone is not an important factor in determining the disposition of nizati dine; however elderly patients may have reduced renal function. See 4 DOSAGE AND ADMINISTRATION; 7.4 WARNINGS AND PRECAUTIONS, Geriatrics; and 10.3 CLINICAL PHARMACOLOGY, Pharmacokinetics, Elimination . https://pdf.hres.ca/dpd_pm/00062205.PDF PM date: July 20, 2021 Source product: AXID; DIN 00778338; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)